Skip to content
2000
Volume 25, Issue 12
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The development of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs), such as Roxadustat (ROX), Enarodustat (ENA), Desidustat (DES), Vadadustat (VAD), Molidustat (MOL), and Daprodustat (DAP), has significant effects on anemia in chronic kidney disease. This review presents comprehensive information about the synthesis, pharmacology, and analysis of HIF-PHIs across several matrices. The literature has presented several approaches for quantifying HIF-PHIs in diverse sample matrices. Furthermore, HIF-PHIs exhibit similar modes of action, demonstrating distinct pharmacokinetic parameters. The pharmacological insights encompass their half-life, mechanism of action, absorption, distribution, metabolism, excretion, and therapeutic uses. Research indicates that most studies concentrate on hyphenated methodologies for drug estimation in various biological fluids. Consequently, this study assesses the biological efficacy of HIF-PHIs and elucidates the analytical methodologies currently employed for measurement across various matrices.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266324419241227102847
2025-01-08
2025-10-03

  • From This Site

    /content/journals/ctmc/10.2174/0115680266324419241227102847
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kalantar-ZadehK. AronoffG.R. Hemoglobin variability in anemia of chronic kidney disease.J. Am. Soc. Nephrol.200920347948710.1681/ASN.200707072819211716
     [Google Scholar]
  2. ZuoQ. WangT. ZhuL. LiX. LuoQ. A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients.Ren. Fail.20224419410210.1080/0886022X.2021.202123735156909
     [Google Scholar]
  3. CoyneD.W. GoldsmithD. MacdougallI.C. New options for the anemia of chronic kidney disease.Kidney Int. Suppl.20177315716310.1016/j.kisu.2017.09.00230675430
     [Google Scholar]
  4. FishbaneS. PollockC.A. El-ShahawyM. EscuderoE.T. RastogiA. VanB.P. FrisonL. HouserM. PolaM. LittleD.J. GuzmanN. PergolaP.E. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 ROCKIES study.J. Am. Soc. Nephrol.202233485086610.1681/ASN.202011163835361724
     [Google Scholar]
  5. WishJ.B. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin.Kidney Int. Rep.20216102540255310.1016/j.ekir.2021.05.02834622095
     [Google Scholar]
  6. HabasE. RayaniA. HabasA.M. AkbarR.A. KhanF.Y. ElzoukiA.N. Anemia in chronic kidney disease patients: An update.Ibnosina J. Med. Biomed. Sci.202214100601110.1055/s‑0042‑1748774
     [Google Scholar]
  7. MinutoloR. LibertiM.E. SimeonV. SassoF.C. BorrelliS. De NicolaL. GarofaloC. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials.Clin. Kidney J.2024171sfad14310.1093/ckj/sfad14338186871
     [Google Scholar]
  8. RenS. YaoX. LiY. ZhangY. TongC. FengY. Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses.Front. Pharmacol.202314129670210.3389/fphar.2023.129670238099145
     [Google Scholar]
  9. Study of roxadustat conversion in participants receiving stable erythropoiesis-stimulating agent (ESA) or as initial anemia treatment in chronic dialysis participants.NCT044101982022
  10. Study of roxadustat conversion in participants receiving stable ESA or as initial anemia treatment in hemodialysis participants (ASPEN).NCT044848572022
  11. Evaluate the efficacy and safety of multiple roxadustat dosing regimens for the treatment of anemia in dialysis participants with chronic kidney disease.NCT040599132022
  12. Effect of hemodialysis on the PK of JTZ-951 in subjects with end-stage renal disease.NCT019785872014
  13. Safety, tolerability, PK & PD study of JTZ-951 in anemic subjects with end-stage renal disease.NCT019711642014
  14. A study to evaluate efficacy and safety of JTZ-951 compared to darbepoetin alfa in korean renal anemia patients receiving hemodialysis.NCT040275172021
  15. Desidustat in the treatment of anemia in CKD (DREAM-ND).NCT040129572021
  16. Desidustat in the treatment of anemia in CKD on dialysis patients (DREAM-D).NCT042151202021
  17. Desidustat in the management of COVID-19 patients.NCT044636022021
  18. Desidustat in the treatment of chemotherapy induced anemia.NCT046675332022
  19. Trial evaluating the efficacy and safety of oral vadadustat once daily (QD) and three times weekly (TIW) for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis-stimulating agents (ESAs).NCT043131532022
  20. Efficacy and safety study to evaluate vadadustat for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).NCT028658502022
  21. Efficacy and safety study to evaluate vadadustat for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD).NCT028921492022
  22. A study of molidustat for correction of renal anemia in non-dialysis subjects (MIYABI ND-C).NCT033503212021
  23. A study of molidustat for maintenance treatment of renal anemia in non-dialysis subjects (MIYABI ND-M).NCT033503472021
  24. A study of molidustat for correction of renal anemia in dialysis subjects (MIYABI HD-C).NCT033511662021
  25. A study of molidustat for treatment of renal anemia in peritoneal dialysis subjects (MIYABI PD).NCT034181682021
  26. Maintenance treatment of renal anemia in dialysis subjects (MIYABI HD-M).NCT035436572021
  27. Anemia studies in chronic kidney disease: Erythropoiesis via a novel prolyl hydroxylase inhibitor daprodustat-non-dialysis (ASCEND-ND).NCT028768352024
  28. Anemia studies in chronic kidney disease: erythropoiesis via a novel prolyl hydroxylase inhibitor daprodustat-dialysis (ASCEND-D).NCT028793052021
  29. Anemia studies in chronic kidney disease (CKD): Erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat in non-dialysis subjects evaluating hemoglobin (Hgb) and quality of life (ASCEND-NHQ).NCT034091072024
  30. Anemia studies in chronic kidney disease (CKD): Erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat-in incident dialysis (ASCEND-ID).NCT030292082021
  31. Anemia studies in chronic kidney disease (CKD): Erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat-three-times weekly dosing in dialysis (ASCEND-TD).NCT034000332021
  32. LautreC. SharmaS. SahuJ.K. Chemistry, biological properties and analytical methods of levonadifloxacin: A review.Crit. Rev. Anal. Chem.20225251069107710.1080/10408347.2020.185541233307757
     [Google Scholar]
  33. BeuckS. SchänzerW. ThevisM. Hypoxia‐inducible factor stabilizers and other small‐molecule erythropoiesis‐stimulating agents in current and preventive doping analysis.Drug Test. Anal.201241183084510.1002/dta.39022362605
     [Google Scholar]
  34. KallemD.J. ThipparaboinaR. PathivadaD. PeddyV. GopiS.P. Polymorphs and co-crystals of roxadustat.WO Patent 2019030711A12019
  35. Enarodustat.Available from: https://go.drugbank.com/drugs/DB14985 (Accessed on: August 6, 2022)
  36. Desidustat.Available from: https://go.drugbank.com/drugs/DB16135 (Accessed on: July 22, 2022)
  37. Vadadustat.Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Vadadustat (Accessed on: September 15, 2022)
  38. Molidustat.Available from: https://go.drugbank.com/drugs/DB15642 (Accessed on: August 5, 2022).
  39. ŠamecD.S. LandekaI. TravančićV. Solid state forms of daprodustat and process for preparation thereof.WO Patent 2020102302A12020
  40. PawarN. BhardwajA. VoraA. SharmaS. A multianalyte LC-MS/MS method for accurate quantification of Nitrosamines in Olmesartan tablets.J. Chromatogr. A2024173246517610.1016/j.chroma.2024.46517639088899
     [Google Scholar]
  41. NovákováL. SvobodaP. PavlíkJ. Chapter 29 - Ultra-high performance liquid chromatography.Liquid ChromatographyElsevier201771976910.1016/B978‑0‑12‑805393‑5.00029‑4
     [Google Scholar]
  42. KrebsF. ZagstH. SteinM. RatihR. MinknerR. OlabiM. Strategies for capillary electrophoresis: Method development and validation for pharmaceutical and biological applications - Updated and completely revised edition.Electrophoresis20234417-181279134110.1002/elps.202300158
     [Google Scholar]
  43. SteinerD. MalachováA. SulyokM. KrskaR. Challenges and future directions in LC-MS-based multiclass method development for the quantification of food contaminants.Anal. Bioanal. Chem.20214131253410.1007/s00216‑020‑03015‑733188454
     [Google Scholar]
  44. DamleM.C. SonuleJ.A. Hydrolytic degradation study of roxadustat by RP-HPLC and HPTLC.Int. J. Pharm. Pharm. Sci.20232023364910.22159/ijpps.2023v15i8.48355
     [Google Scholar]
  45. PatelR. YadavP. Stability indicating RP-HPLC method development and validation for estimation of desidustat in tablet dosage form.WwwWjppsCom201512129010.20959/wjpps20237‑25215
     [Google Scholar]
  46. ZhengX. ChenX. LiuT. JiangJ. CuiX. ZhaoQ. HuP. Liquid chromatography-tandem mass spectrometry methods for quantification of roxadustat (FG-4592) in human plasma and urine and the applications in two clinical pharmacokinetic studies.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2022120312327410.1016/j.jchromb.2022.12327435662878
     [Google Scholar]
  47. MazzarinoM. PerrettiI. StacchiniC. ComunitàF. de la TorreX. BotrèF. UPLC–MS-based procedures to detect prolyl-hydroxylase inhibitors of HIF in urine.J. Anal. Toxicol.202145218419410.1093/jat/bkaa05532435795
     [Google Scholar]
  48. MathewB. PhilipM. PerwadZ. KarattT.K. CaveneyM.R. SubhaharM.B. Karakka KalA.K. Identification of Hypoxia‐inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control.Drug Test. Anal.20211361203121510.1002/dta.301433569900
     [Google Scholar]
  49. ProvenzanoR. TumlinJ. ZabanehR. ChouJ. HemmerichS. NeffT.B. YuK.H.P. Oral hypoxia‐inducible factor prolyl hydroxylase inhibitor roxadustat (FG‐4592) for treatment of anemia in chronic kidney disease: A placebo‐controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients.J. Clin. Pharmacol.202060111432144010.1002/jcph.164832603526
     [Google Scholar]
  50. SaigusaD. SuzukiN. MatsumotoY. UmedaK. TomiokaY. KoshibaS. YamamotoM. Retracted: Detection of novel metabolite for Roxadustat doping by global metabolomics.J. Biochem.201810.1093/jb/mvy02829438490
     [Google Scholar]
  51. HanssonA. ThevisM. CoxH. MillerG. EichnerD. BondessonU. HedelandM. Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry.J. Pharm. Biomed. Anal.201713422823610.1016/j.jpba.2016.11.04127918992
     [Google Scholar]
  52. Groenendaal-van de MeentD. AdelM. NoukensJ. RijndersS. Krebs-BrownA. MatevaL. AlexievA. SchaddeleeM. Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.Clin. Drug Investig.201636974375110.1007/s40261‑016‑0422‑y27352308
     [Google Scholar]
  53. BuissonC. MarchandA. BaillouxI. LahaussoisA. MartinL. MolinaA. Detection by LC–MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case.J. Pharm. Biomed. Anal.201612118118710.1016/j.jpba.2016.01.02926808067
     [Google Scholar]
  54. PaiS. HuangM.Q. MakiK. WaldronM. YoshikawaT. KellerT. BurnettJ. A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2021117612275410.1016/j.jchromb.2021.12275434052557
     [Google Scholar]
  55. PaiS.M. ConnaireJ. YamadaH. EnyaS. GerhardtB. MaekawaM. TanakaH. KoretomoR. IshikawaT. A mass balance study of 14 C‐labeled JTZ‐951 (Enarodustat), a novel orally available erythropoiesis‐stimulating agent, in patients with end‐stage renal disease on hemodialysis.Clin. Pharmacol. Drug Dev.20209672874110.1002/cpdd.75231876104
     [Google Scholar]
  56. GarzinskyA.M. ThomasA. KrugO. ThevisM. Probing for the presence of doping agents in exhaled breath using chromatographic/mass spectrometric approaches.Rapid Commun. Mass Spectrom.2021351e893910.1002/rcm.893932881194
     [Google Scholar]
  57. PatelH. SoniK. TrivediR. HeadingH. GeueJ. KansagraK. GuptaR.J. PandyaV.B. SrinivasN.R. PatelP.R. DesaiR.C. A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization.Bioanalysis20179971973210.4155/bio‑2017‑001428488896
     [Google Scholar]
  58. ChavanA. BurkeL. SawantR. Navarro-GonzalesP. VargoD. PaulsonS.K. Effect of moderate hepatic impairment on the pharmacokinetics of vadadustat, an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor.Clin. Pharmacol. Drug Dev.202110895095810.1002/cpdd.92733661566
     [Google Scholar]
  59. DibJ. MongonguC. BuissonC. MolinaA. SchänzerW. ThussU. ThevisM. Mass spectrometric characterization of the hypoxia‐inducible factor (HIF) stabilizer drug candidate BAY 85‐3934 (molidustat) and its glucuronidated metabolite BAY‐348, and their implementation into routine doping controls.Drug Test. Anal.201791616710.1002/dta.201127346747
     [Google Scholar]
  60. ThevisM. MilosovichS. Licea-PerezH. KnechtD. CavalierT. SchänzerW. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.Drug Test. Anal.20168885886310.1002/dta.187026361079
     [Google Scholar]
  61. PaiS.M. YamadaH. Hemodialysis clearance of enarodustat (JTZ‐951), an oral erythropoiesis stimulating agent, in patients with end‐stage renal disease.Clin. Pharmacol. Drug Dev.202110546347010.1002/cpdd.92333788422
     [Google Scholar]
  62. PíšaO. RádlS. ČerňaI. ŠemberaF. A scalable synthesis of roxadustat (FG-4592).Org. Process Res. Dev.202123391592410.1021/acs.oprd.1c00281
     [Google Scholar]
  63. ZhikunY. LeiP. WeiH. LonglinW. YanZ. Preparation method of Rosxastat.CN Patent 111533691A2020
  64. XuchunZ. YipingZ. Preparation method of medicine for treating chronic anemia.CN Patent 108424388B2020
  65. MitaniI. MitaniI. OgoseY. TakuyaM. MatsuiT. YokotaM. MasaM.T. TerashitaK. Triazolopyridine compounds and their action as prolyl hydroxylase inhibitors and erythropoietin production inducers.JP Patent 6434575B22018
  66. SharmaR. Process of preparation of quinolone based compounds.2019
     [Google Scholar]
  67. KawamotoR.M. WuS. EvdokimovA.G. GreisK.D. BoyerA.S. WarshakoonN.C. Prolyl hydroxylase inhibitors and method of use.US Patent8722895B22014
  68. ThedeK. FlammeI. OehmeF. ErgüdenJ.K. StollF. SchuhmacherJ. WildH. KolkhofP. BeckH. KeldenichJ. Substituted dihydropyrazolones for treating cardiovascular and hematological diseases.US Patent 8987261B22015
  69. DuffyK.J. FitchD.M. JinJ. LiuR. ShawA.N. WiggallK. Prolyl hydroxylase inhibitors.WO Patent 2007150011A22007
  70. PortolésJ. MartínL. BrosetaJ.J. CasesA. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.Front. Med. (Lausanne)2021864229610.3389/fmed.2021.64229633842503
     [Google Scholar]
  71. Roxadustat.Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11256664 (Accessed on: August 22, 2022)
  72. RekićD. Kerbusch-HerbenV. NågårdM. ChouJ. HuangJ. BradleyC. ÅstrandM. TannenbaumS. HamrénB. Pharmacokinetics of roxadustat: A population analysis of 2855 dialysis- and non-dialysis-dependent patients with chronic kidney disease.Clin. Pharmacokinet.202160675977310.1007/s40262‑020‑00974‑z33486718
     [Google Scholar]
  73. CzockD. KellerF. Clinical pharmacokinetics and pharmacodynamics of roxadustat.Clin. Pharmacokinet.202261334736210.1007/s40262‑021‑01095‑x34905154
     [Google Scholar]
  74. FujikawaR. NagaoY. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.Ther. Apher. Dial.202226467969310.1111/1744‑9987.13820
     [Google Scholar]
  75. MarkhamA. Enarodustat: First approval.Drugs202181116917410.1007/s40265‑020‑01444‑333320297
     [Google Scholar]
  76. FukuiK. ShinozakiY. KobayashiH. DeaiK. YoshiuchiH. MatsuiT. MatsuoA. MatsushitaM. TanakaT. NangakuM. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.Eur. J. Pharmacol.201985917253210.1016/j.ejphar.2019.17253231301309
     [Google Scholar]
  77. AkizawaT. NangakuM. YamaguchiT. AraiM. KoretomoR. MaedaK. MiyazawaY. HirakataH. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: A randomized, placebo-controlled phase 2b trial followed by long-term trial.Nephron J.20191432778510.1159/00050048731117088
     [Google Scholar]
  78. KansagraK.A. ParmarD. JaniR.H. SrinivasN.R. LickliterJ. PatelH.V. ParikhD.P. HeadingH. PatelH.B. GuptaR.J. ShahC.Y. PatelM.R. DholakiaV.N. SukhadiyaR. JainM.R. ParmarK.V. BarotK. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers.Clin. Pharmacokinet.20185718710210.1007/s40262‑017‑0551‑328508936
     [Google Scholar]
  79. JainM. JoharapurkarA. PatelV. KshirsagarS. SutariyaB. PatelM. PatelH. PatelP.R. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.Eur. J. Pharmacol.201984311312010.1016/j.ejphar.2018.11.02330458168
     [Google Scholar]
  80. HuangQ. LiaoZ. LiuX. XiaY. WangJ. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: A meta-analysis.Int. Urol. Nephrol.202255232533410.1007/s11255‑022‑03316‑z35960479
     [Google Scholar]
  81. LentiniS. KaiserA. KapsaS. MatsunoK. van der MeyD. Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: An oral HIF–PH inhibitor for the treatment of renal anaemia.Eur. J. Clin. Pharmacol.202076218519710.1007/s00228‑019‑02813‑y31919558
     [Google Scholar]
  82. LentiniS. van der MeyD. KernA. ThussU. KaiserA. MatsunoK. GerischM. Absorption, distribution, metabolism and excretion of molidustat in healthy participants.Basic Clin. Pharmacol. Toxicol.2020127322123310.1111/bcpt.1340932248614
     [Google Scholar]
  83. YamamotoH. NoboriK. MatsudaY. HayashiY. HayasakiT. AkizawaT. Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: A randomized, phase 3 trial.Am. J. Nephrol.20215210-1187188310.1159/00051807134569489
     [Google Scholar]
  84. MaharK.M. ShaddingerB.C. RamanjineyuluB. AndrewsS. CaltabianoS. LindsayA.C. CobitzA.R. Pharmacokinetics of daprodustat and metabolites in individuals with normal and impaired hepatic function.Clin. Pharmacol. Drug Dev.202211556257510.1002/cpdd.109035355447
     [Google Scholar]
  85. LabesR. BrinkmannL. KulowV.A. RoegnerK. MathiaS. BalcerekB. PerssonP.B. RosenbergerC. FählingM. Daprodustat prevents cyclosporine-A–mediated anemia and peritubular capillary loss.Kidney Int.2022102475076510.1016/j.kint.2022.04.02535643373
     [Google Scholar]
  86. HorváthI.T. AnastasP.T. Innovations and green chemistry.Chem. Rev.200710762169217310.1021/cr078380v17564478
     [Google Scholar]
  87. GaikwadJ. SharmaS. HatwareK.V. Review on characteristics and analytical methods of tazarotene: An update.Crit. Rev. Anal. Chem.2020501909610.1080/10408347.2019.158651930942085
     [Google Scholar]
  88. KumariS. SharmaA. KumarS. ThakurA. ThakurR. BhatiaS.K. SharmaA.K. Multifaceted potential applicability of hydrotalcite-type anionic clays from green chemistry to environmental sustainability.Chemosphere202230613546410.1016/j.chemosphere.2022.13546435760140
     [Google Scholar]
  89. BeckerJ. ManskeC. RandlS. Green chemistry and sustainability metrics in the pharmaceutical manufacturing sector.Curr. Opin. Green Sustain. Chem.20223310056210.1016/j.cogsc.2021.100562
     [Google Scholar]
/content/journals/ctmc/10.2174/0115680266324419241227102847
Loading
Bioanalysis, Analysis, Chemistry, and Pharmacological Aspects of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
Curr. Top. Med. Chem. 25, 1451 (2025); https://doi.org/10.2174/0115680266324419241227102847
/content/journals/ctmc/10.2174/0115680266324419241227102847
/content/journals/ctmc/10.2174/0115680266324419241227102847
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): analysis; chemistry; chronic kidney disease; HIF-PHIs; pharmacology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test